Loading...
•
Mar 31
Edwards Lifesciences Q1 2025 Earnings Report
Edwards Lifesciences reported solid financial performance in Q1 2025 with increased revenue and profitability.
Key Takeaways
The company delivered a strong start to 2025, with notable growth in TMTT and steady gains in TAVR. EPS and net income improved, bolstered by product adoption and operational efficiency.
Revenue grew to $1.41 billion, a 6.2% increase year-over-year.
Transcatheter Mitral and Tricuspid Therapies (TMTT) surged 58% to $115 million.
Adjusted EPS reached $0.64, exceeding expectations.
Gross profit margin improved slightly to 78.7%.
Edwards Lifesciences
Edwards Lifesciences
Edwards Lifesciences Revenue by Segment
Edwards Lifesciences Revenue by Geographic Location
Revenue by Segment
TAVR Revenue
CapyFin.comTMTT Revenue
CapyFin.comSurgical Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.comJapan Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
Edwards Lifesciences reaffirmed its 2025 EPS and sales guidance, with optimism around product momentum despite macroeconomic headwinds.
Positive Outlook
- Raised 2025 TMTT sales guidance to $530M–$550M.
- Total 2025 sales now expected to be $5.7B–$6.1B.
- Reaffirmed full-year adjusted EPS guidance of $2.40–$2.50.
- Continued global adoption of new technologies like SAPIEN M3 and EVOQUE.
- Strong start to the year supports confidence in long-term growth strategy.
Challenges Ahead
- Expectations of margin pressure from weakening dollar.
- Tariff impacts could increase operational costs.
- Pending acquisition of JenaValve may bring dilution.
- Limited growth in Surgical segment (only 1% YoY).
- Slight revenue decline in Japan due to demographic and market dynamics.
Revenue & Expenses
Visualization of income flow from segment revenue to net income